MTOR and lung carcinoma: As mTOR is one of the downstream substrates of FBXW7 and a case study of a lung cancer patient harboring an FBXW7 mutation reported clinical and radiographic benefit from treatment with an mTOR inhibitor (Villaruz and Socinski, 2014), we addressed the possibility that FBXW7 executed its role in gefitinib treatment through interfering mTOR signaling pathway.